ATOSSA THERAPEUTICS, INC. 8-K

What Happened
Atossa Therapeutics, Inc. (NASDAQ: ATOS) filed a Form 8-K on January 9, 2026, making an updated corporate presentation publicly available (Exhibit 99.1). The presentation estimated that the company had approximately $40 million in cash and cash equivalents as of December 31, 2025. The report was signed by Mark J. Daniel, Chief Financial Officer. The filing also referenced Regulation FD disclosure.

Key Details

• The corporate presentation is dated January 9, 2026 and was attached to the Form 8-K as Exhibit 99.1.
• Cash and cash equivalents were estimated at approximately $40 million as of December 31, 2025.
• The 8-K was filed under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
• The filing did not present detailed quarterly revenue or earnings figures—it provided a liquidity snapshot via the presentation.

Why It Matters
A stated cash balance is a key liquidity metric for biotech companies funding research and clinical programs. The approximately $40M figure gives investors a recent snapshot of Atossa’s available cash resources and can help assess near-term financing and operational runway. The Regulation FD disclosure indicates the company publicly shared this information to keep investors informed.